Prolonged decrease of adipocyte size after rosiglitazone treatment in high- and low-fat-fed rats

Obesity

Volumn 15, Issue 11, 2007, Pages 2653-2663

  Johnson, Julia A ^a   Trasino, Steven E ^a   Ferrante Jr , Anthony W ^a   Vasselli, Joseph R ^a,b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Adiponectin; Adipose tissue; Body weight; Food intake; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ANTIDIABETIC AGENT; INSULIN; LEPTIN; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL; ARTICLE; BIOPSY; BLOOD; BODY WEIGHT; CELL SIZE; COMPARATIVE STUDY; DRUG EFFECT; EATING; FAT INTAKE; FEMALE; OBESITY; PATHOLOGY; RANDOMIZATION; RAT; SPRAGUE DAWLEY RAT;

ADIPOCYTES; ADIPONECTIN; ADIPOSE TISSUE; ADIPOSITY; ANIMALS; BIOPSY; BODY WEIGHT; CELL SIZE; DIETARY FATS; EATING; FEMALE; HYPOGLYCEMIC AGENTS; INSULIN; LEPTIN; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES; TRIGLYCERIDES;

ANIMALIA; RATTUS;

EID: 38049047703     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2007.317     Document Type: Article

References (46)

1. Ferré P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes. 2004;53:S43-50.
2. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996;45: 1661-9.
3. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkinson WO, Wilson TM, Kliewer SA. An anti-diabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma. J Biol Chem. 1995; 270:12953-6.
4. de Souza CJ, Eckhardt M, Gagen K, et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes. 2001;50: 1863-71.
5. Hallakou S, Doaré L, Foufelle F, et al. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes. 1997;146:1393-9.
6. Okuno T, Tobe K, Ueki K, et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest. 1998; 101:1354-61.
7. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab. 2004;89:463-78.
8. Ye J-M, Dzamko N, Cleasby ME, et al. Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin. Diabetologia. 2004;47: 1306-13.
9. Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004; 351:1106-18.
10. Maeda N, Takahashi M, Funahashi T, et al. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50: 2094-9.
11. Combs TP, Wagner JA, Berger J, et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology. 2002;143:998-1007.
12. Yu JG, Javorschi S, Hevener AL, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes. 2002;51:2968-74.
13. Pajvani UB, Hawkins M, Combs TP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem. 2004;279:12152-62.
14. Rasouli N, Yao-Borengasser A, Miles LM, Elbein SC, Kern PA. Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. Am J Physiol. 2006;290:E42-6.
15. De Vos P, Lefebvre AM, Miller SG, et al. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J Clin Invest. 1996;98:1004-9.
16. Kallen C, Lazar MA. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Cell Biol. 1996;93:5793-6.
17. Shimizu H, Tsuchiya T, Sato N, Shimomura Y, Kobayashi I, Mori M. Troglitazone reduces plasma leptin concentration but increases hunger in type 2 diabetes patients. Diabetes Care. 1998;21:1470-4.
18. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112:1821-30.
19. Hofmann C, Lorenz K, Braithwaite SS, et al. Altered gene expression for tumor necrosis factor-α and its receptors during drug and dietary modulation of insulin resistance. Endocrinology. 1994;134:264-70.
20. Bruun JM, Lihn AS, Pedersen SB, Richelsen B. Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J Clin Endocrinol Metab. 2005; 90:2282-8.
21. Di Gregorio GB, Yao-Borengasser A, Rasouli N, et al. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes. 2005;54:2305-13.
22. Weisberg SP, Hunter D, Huber R, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest. 2006;116:115-24.
23. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51: 2796-803.
24. Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005;54:1150-6.
25. Padwal R, Majumdar SR, Johnson JA, Varney J, McAlister FA. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care. 2005;28:736-44.
26. Wang Q, Dryden S, Frankish HM, et al. Increased feeding in fatty Zucker rats by the thiazolidinedione BRL 49653 (rosiglitazone) and the possible involvement of leptin and hypothalamic neuropeptide Y. Br J Pharmacol. 1997;122: 1405-10.
27. Pickavance LC, Buckingham RE, Wilding JPH. Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia. Diabetes Obesity Metab. 2001;3:171-80.
28. Larsen PJ, Jensen PB, Sørensen RV, et al. Differential influences of peroxisome proliferator-activated receptors gamma and alpha on food intake and energy homeostasis. Diabetes. 2003;52:2249-59.
29. Larsen TM, Toubro S, Astrup A. PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? Int J Obesity. 2003;27:147-61.
30. Vasselli JR, Fiene JA, Maggio CA. Relationship of adipocyte size to hyperphagia in developing male obese Zucker rats. Am J Physiol. 1992;262:R33-8.
31. Johnson JA, Yu CH, Yang MU, Pi-Sunyer FX. Protein conservation is altered in aging Sprague-Dawley rats during severe energy restriction. Obes Res. 1998;6:448-57.
32. Hirsch J, Gallian E. Methods for the determination of adipose cell size in man and animals. J Lipid Res. 1968;9:100-19.
33. Folch J, Leek M, Sloane-Stanley GH. A simple method for isolation and purification of total lipids from animal tissues. J Biol Chem. 1957;226:497-509.
34. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1796-808.
35. Chen HC, Farese RV Jr. Determination of adipocyte size by computer image analysis. J Lipid Res. 2002,43:986-9.
36. Löfgren P, Andersson I, Adolfsson B, et al. Long-term prospective and controlled studies demonstrate adipose tissue hypercellularity and relative leptin deficiency in the postobese state. J Clin Endocrinol Metab. 2005;90: 6207-13.
37. Berthiaume M, Sell H, Lalonde J, et al. Actions of PPARγ agonism on adipose tissue remodeling, insulin sensitivity, and lipemia in absence of glucocorticoids. Am J Physiol. 2004; 287:R1116-23.
38. Smith SR, de Jonge L, Volaufova J, Li Y, Xie H, Bray GA. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism Clin Exp. 2005;54:24-32.
39. Fried SK, Hill JO, Nickel M DiGirolamo M. Prolonged effects of fasting-refeeding on rat adipose tissue lipoprotein lipase activity: influence of caloric restriction during refeeding. J Nutr. 1983;113:1861-9.
40. Cleary MP. Consequences of restricted feeding/refeeding cycles in lean and obese female Zucker rats. J Nutr. 1986;116: 290-303.
41. Uhley VE, Jen KL. Changes in feeding efficiency and carcass composition in rats on repeated high-fat feedings. Int J Obes. 1989;13:849-56.
42. Sea M-M, Fong WP, Huang Y, Chen Z-U. Weight cycling-induced alteration in fatty acid metabolism. Am J Physiol. 2000;279:R1145-55.
43. Jiang G, Dallas-Yang Q, Li Z, et al. Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPARγ agonists. Diabetes. 2002;51:2412-9.
44. Tonelli J, Li W, Kishore P, et al. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes. 2004;53:1621-9.
45. Hammarstedt A, Rotter Sopasakis V, Gogg S, Jansson PA, Smith U. Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects. Diabetologia. 2005; 48:96-104.
46. Xiang AH, Peters RK, Kjos SL, et al. Effect of pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes. 2006;55: 517-22.